Drugs / 11D10
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00045617 | Jan → May 2003 | lung cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT00033748 | Dec 2001 → Mar 2007 | colorectal cancer, metastatic malignant neoplasm | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 2 | NCT00006470 | Mar 2001 → Dec 2004 | lung cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11D10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006470 ↗ |
| Known as | TriAb | “Patients also receive monoclonal antibody 11D10 anti-idiotype vaccine (TriAb) and monoclonal antibody GD2 anti-idiotype vaccine (TriGem) intradermally on day 1 of weeks 11, 13,...” NCT00045617 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody 11D10 anti-idiotype vaccine” NCT00006470 ↗ |
| Route | Other | “intracutaneously in separate sites” NCT00006470 ↗ |